Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor anta

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor anta

Item
http://www.wikidata.org/entity/Q28203499
Q28159308
sameAs
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.Vasopressin: behavioral roles of an "original" neuropeptideThe hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptorsThe Vasopressin 1b Receptor Antagonist A-988315 Blocks Stress Effects on the Retrieval of Object-Recognition Memory.Oxytocin-induced contractions within rat and rabbit ejaculatory tissues are mediated by vasopressin V1A receptors and not oxytocin receptorsThe vasopressin Avpr1b receptor: molecular and pharmacological studies.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsOxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?Attenuated stress response to acute restraint and forced swimming stress in arginine vasopressin 1b receptor subtype (Avpr1b) receptor knockout mice and wild-type mice treated with a novel Avpr1b receptor antagonistVasopressin inhibits LTP in the CA2 mouse hippocampal area.The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions.Vasotocin and vasopressin stimulation of the chloride secretion in the human bronchial epithelial cell line, 16HBE14o-.Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonistNicotine stimulates secretion of corticosterone via both CRH and AVP receptors.Attenuated stress response to acute lipopolysaccharide challenge and ethanol administration in vasopressin V1b receptor knockout mice.Chronic treatment with the vasopressin 1b receptor antagonist SSR149415 prevents the dysphoria associated with nicotine withdrawal in ratsInnovative approaches for the development of antidepressant drugs: current and future strategiesThe parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stressVasopressin does not mediate hypersensitivity of the hypothalamic pituitary adrenal axis during chronic stressA novel experimental strategy to assess the metabolic effects of selective activation of a G(q)-coupled receptor in hepatocytes in vivo.Role of enteroendocrine L-cells in arginine vasopressin-mediated inhibition of colonic anion secretion.Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.Arginine Vasopressin Alters Both Spontaneous and Phase-Locked Synaptic Inputs to Airway Vagal Preganglionic Neuron via Activation of V1a Receptor: Insights into Stress-Related Airway Vagal Excitation.Novel insights into M3 muscarinic acetylcholine receptor physiology and structure.Stress-related depression: neuroendocrine, genetic, and therapeutical aspects.Advances in nicotine research in Addiction Biology.Vasopressin and metabolic disorders: translation from experimental models to clinical use.Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand.Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.Haemodynamic and renal sympathetic responses to V1b vasopressin receptor activation within the paraventricular nucleus.Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.Persistent increase in hypothalamic arginine vasopressin gene expression during protracted withdrawal from chronic escalating-dose cocaine in rodents.Proinflammatory role of vasopressin through V1b receptors in hapten-induced experimental colitis in rodents: implication in IBD.Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice.Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species.Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs.Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor.
P2860
Q24534256-715E80D8-BCFD-4A98-B355-9B47D7448251Q24656284-E908B0B8-1B2E-44A9-8803-AB47F2A93AEEQ24676277-40CCC133-A27E-4CC2-B56C-B82D516720D6Q27310716-39EF74E9-C6E1-45A4-A2CA-DC5622530455Q28576679-FF2CFA96-31E0-4972-8A0B-4B718BB04BFBQ30477659-40867555-69EA-4127-8C4D-FF44BA942E1EQ30486707-73EA3783-A68E-43F2-9588-21B255D86309Q34257617-BA8B1BA7-41C0-41E1-AC3D-6C7BBE181CF4Q34275762-6D853129-31A7-4FA2-BF75-257788E7F363Q34394613-AFC9F48D-8355-4AC9-807F-2E15C1297A85Q34510263-33FFEFE7-84BD-49EA-BDFC-D4FFFB1592F4Q35043245-68CC14F5-B54F-47F6-A427-3BE83CAFE8A1Q35048777-9FE93FCA-DA6C-4005-AACF-9B9C58123F2DQ35545067-1749A4E6-F7C1-42C9-97F1-3E90D78942E6Q35812772-A8112DC7-EF2B-4F90-A2DF-4F6666DA1BEEQ35842919-4A178E1F-8957-41E7-ACE4-9FDC7B765A49Q36021414-945CD46D-20E2-48B2-BD28-4AB8314BCA2DQ36401400-AF6A6929-D4C4-4F8A-A051-65A5ED9FC032Q36877195-E4C07912-B099-445F-A830-2D9B71676198Q37038298-C7FB774C-556C-47B7-957D-7171C1CD679BQ37181904-52EB4B74-2A8B-40CB-BF97-D5204281FB49Q37228951-5427D243-51FD-480E-90E7-354D45A4CD10Q37265054-CE7923CB-CA40-4EE5-A9EB-1CEC93230F6FQ37619980-0DD441BC-CB38-4612-A739-CB9C228FB1BBQ37666222-9BEDF65E-34E0-4B78-8610-2679124AE94EQ38016982-6C8E8A6C-C8D3-47FC-9AB4-B69D75DF78F9Q38495725-32A5B7C4-1E3C-47A1-A8E6-8E0FC0B2778CQ39422254-0D9BB041-C874-4D41-BFBC-1A65A9DC992CQ40128695-C863B112-1E88-4DD5-9F72-C0206982CFF6Q40649344-3A981935-AEA6-443E-89AC-9AB2ADF898EBQ41553298-841B48BC-85E3-41DB-A9CC-B6122C480134Q41786583-215DF0DB-E149-4500-921B-79B243CE6BCFQ41840777-196780C9-01D9-4CB2-A7AA-2C2EE3FF4375Q42877924-E9673BDE-D3A2-463A-AFBB-F1F05022C856Q43139485-80FD26AC-7344-46A6-BB64-EDEE3B2265E0Q44709359-CDD61EC3-E0CF-4BD4-BC9F-8A0FBC224347Q45059328-2351617B-5AFC-404F-8812-2DE19EB5AF71Q46247412-CA93794A-8517-44F1-9BC5-042916FC1A86Q46547612-0FE2A7B9-7B8F-4FA2-AE3B-4054D9A6C6C7Q46933173-AFB69F26-BED7-45FF-890E-B6B7A165DC6E
P2860

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor anta

Item
http://www.wikidata.org/entity/Q28203499
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Characterization of (2S,4R)-1- ...... vasopressin V1b receptor anta
@nl
type
label
Characterization of (2S,4R)-1- ...... vasopressin V1b receptor anta
@nl
prefLabel
Characterization of (2S,4R)-1- ...... vasopressin V1b receptor anta
@nl
P1433
P1476
P2093
P304
P31
P3181
P356
P407
P433
P478
P577
P5875
P698
P921
P3181
P356
P1433
P1476
Characterization of (2S,4R)-1- ...... ressin V1b receptor antagonist
@en
P2093
P304
P31
P3181
P356
P407
P433
P478
P577
P5875
P698
P921